The objective of this paper was to evaluate the cardiovascular risk in white coat hypertension (WCH). WCH is a well-known clinical entity defined by persistently elevated blood pressure (BP) in the doctor's office, whereas BP in other conditions is normal. The prognosis of WCH is unsettled, although two prospective studies that include normal control groups imply that the condition is benign. This study is a 10-year follow-up study on 420 patients with grade I-II hypertension newly diagnosed by their general practitioner and 146 normal controls (NTs). Ambulatory blood pressure (ABP) monitoring was performed at baseline. With our protocollated cutoff value of daytime-ABP o135/ 90 mmHg, 76 (18.1%) of the 420 hypertensives were white coat hypertensives (WCHs) and 344 were established hypertensives (EHs). With a lower cutoff of 135/ 85 mmHg, 40 (9.5%) were WCHs. Complete follow-up data were obtained for all 566 subjects. The mean duration of follow-up was 10.2 years (range 9.0-12.5).
Introduction
White coat hypertension (WCH) has been recognized as a clinical entity approximately since 1987. 1 The condition is defined by hypertensive blood pressure (BP) in the office, whereas BP in other situations is normal. The difference between the two BP measurements is referred to as the white coat effect (WCE), and is primarily due to a positive pressor reaction induced by the clinical visit. The phenomenon was decribed by Riva-Rocci 2 more than 100 years ago and has further been studied and illustrated by Ayman and Goldshine 3 in the 1940s and by Sokolow et al 4 in the 1960s. However, despite this long awareness the knowledge of the adverse effects of WCE is only sparse and particularly the prognosis of WCH remains unsettled; only a few longitudinal studies have been performed in this field [5] [6] [7] [8] and so far the prospective data imply that WCH is a low-risk condition. In all the studies, white coat hypertensives (WCHs) developed fewer cardiovascular events than the established hypertensives (EHs), and in the two studies that included control individuals, these were found to have the same event rate as the WCH patients. 5, 8 However, the inclusion criteria and WCH definition were different in the studies and in three of them the follow-up time was below 4.4 years. 5, 7, 8 Accordingly, there is an evident need for further studies on the prognosis of WCH, especially in the longer term.
We present here 10 years follow-up data on 566 individuals who, according to baseline measurements, were classified as WCHs, EHs and normal controls (NTs).
Material and methods

Study population
This study is based on a longitudinal observation of 566 consecutive individuals subjected to 24-h noninvasive ambulatory blood pressure monitoring (ABPM) at our institution from 1 January 1989 to 30 November 1992. Of these individuals, 420 were newly diagnosed grade I (mild) to grade II (moderate) hypertensives referred consecutively from their general practitioner (GP). All were considered by their GP to have hypertension on the basis of at least three BP measurements (median, 4) with at least weekly intervals. Inclusion criteria were that the average diastolic BP was at least 90 mmHg and that the GP had planned to start antihypertensive treatment but not yet instituted it. The systolic BP was not an inclusion criterion in the original protocol, but none of the patients had a systolic office BP (OBP) below 140 mmHg. No patient had received any antihypertensive drug in the preceding month and no patient had been taken off medication to enter the study; however, 97 patients (23.1%) had previously taken such medication. No patient with cardiovascular diseases was included.
A control group of 146 NTs was drawn at random from the Danish National Register. These individuals were recruited as part of a multicentre study that should establish the distribution of ambulatory BP (ABP) in the population. Subjects with known renal or cardiovascular disease, diabetes, hypertension or other conditions necessitating drugs with antihypertensive effects were excluded. Baseline evaluation included a detailed medical history, OBP and ABPM; these data have been reported previously. [9] [10] [11] [12] [13] All subjects gave their informed consent. The study was conducted in accordance with the second declaration of Helsinki and was approved by the local ethics committee.
Office blood pressure
The BP was measured by the GP according to routines and without any instructions from the study group. The mean of the OBPs was above or equal to 140/90 mmHg in all referred patients and the average of these measurements was used in the calculations (doctors OBP).
In order to check the correctness of the ABPM equipment, we performed five simultaneous measurements with a Hawksley random zero sphygmomanometer. These measurements took place in a quiet room, in a relaxed atmosphere over 30-40 min with the doctor present during the whole period. OBP was the mean of the five device measurements (our OBP).
Ambulatory blood pressure monitoring
The ABPM was performed with the A&D TM2420 monitor (Osaka, Japan), 14 which measures BP by the auscultatory technique. The monitors performed measurements every 15 min from 0700 to 2259 and every half hour from 2300 to 0659. The patients wore the monitors for 24 h, almost exclusively on working days, during which period they went about their normal activities.
We defined WCH as having an average daytime ABP o135 mmHg systolic and o90 mmHg diastolic. This cutoff level was predefined in the study protocol and was based on our own cross-sectional results. When applying this partition value, the WCHs and NTs did not differ with respect to cardiac and renal target organ damage. 12 However, recent consensus is that 135/85 mmHg should be used as a cut-off for daytime ABP, therefore calculations was performed using this cutoff as well. 15 Daytime and night-time ABP were calculated using the 'narrow fixed-clock intervals' (daytime period from 0800 to 2200, night time from 0000 to 0600).
BP management
After the patients were enrolled in the study, the GPs were informed of the results of the ABPM. Subsequent BP control and treatment was left to the GP. It was generally recommended that antihypertensive treatment was based on OBP since ABP was considered as an investigational result.
End point evaluation
All hospital contacts, both admissions and outpatient clinic visits, were identified from the Danish Patient Registers. In order to obtain complete information on cardiovascular events and antihypertensive medication during the follow-up period, all the records from the hospital and GP for each patient were collected and reviewed to identify and document end points. When reviewing the records, the authors were strictly blinded regarding the classification of the individual and the results of the ABPM. An end point was accepted when consensus was obtained between the four investigators.
Documented end points were classified as fatal and nonfatal cardiovascular events and as all-cause mortality. The primary end point was a composite end point including morbidity and mortality caused by myocardial infarction, angina pectoris, coronary revascularization, sudden death, stroke, transient cerebral ischaemic attack, dissecting aortic aneurysm, claudication (verified by angiogram), heart failure, renal artery stenosis and carotid artery ste-nosis. 5 Analysis was also performed on a composite end point of major cardiovascular events including only the first seven of the above-listed events. All-cause mortality was the secondary end point.
Statistical analysis
SPSS version 10.1 (SPSS Inc., Chicago, IL, USA) was used to perform the analyses. Parametric data are reported as mean 7 s.d. w 2 -test was used for group comparisons for categorized data. For the subjects who experienced multiple events, survival analysis was based on the first event. Survival curves were estimated using the Kaplan-Meier product-limit method and were compared by the Mantel log-rank test. The effect of prognostic factors on survival was evaluated by the stepwise Cox-semiparametric regression model. The following variables were tested: age, sex, daytime systolic ABP, daytime diastolic ABP, OBP, BMI, smoking history, previous cardiovascular disease, diabetes. Po0.05 was considered to be statistically significant.
Results
Demographic data
Of the 566 subjects, 76 were WCHs, 344 were EHs and 146 were NTs. The prevalence of WCH was 18.1% among the 420 referred hypertensives. Demographic data including frequency of treatment at any time before the inclusion and during follow-up are shown in Table 1 . The significant difference in age is explained by an intended even-age stratification when recruiting the NT group. Details of antihypertensive treatment were available for all subjects. The median duration of treatment started during followup was 94, 39 and 2 months, respectively, for EHs, WCHs and NTs, respectively.
Haemodynamic data
Baseline OBP and ABP of the three groups are shown in Table 1 . In accordance with the definition, daytime systolic and diastolic ABP were significantly lower in the group with WCH than in the group with EH. Also, systolic daytime ABP in the WCH group was significantly lower than in the NT group. Office systolic and diastolic BP, as expected, were significantly higher in the WCH group than in the NT group, but also significantly lower than in the EH group.
Comparison of events
We obtained complete follow-up data for all 566 subjects; this 100% follow-up was made possible by the 10-digit personal ID number of all Danish citizens. The mean duration of follow-up was 10.2 years (range 9-12.5). During this period, 60 subjects died, 20 of these from a cardiovascular event, and 64 developed a nonfatal first cardiovascular event. The distribution of first cardiovascular events is given in Table 2 . The number and causes of death in the three groups are listed in Table 3 .
In the WCH group, 14 first events were recorded consisting of two cardiovascular deaths and 12 nonfatal cardiovascular events. In the EH group, the corresponding number of events were 56 first events, 12 cardiovascular deaths and 44 nonfatal cardiovascular events, and in the NT group 10 first events, two cardiovascular deaths and eight nonfatal cardiovascular events. The event rate was similar in the WCH and the EH groups and significantly higher than in the NT group (P ¼ 0.03 overall, P ¼ 0.03 between WCH and NT and P ¼ 0.01 between EH and NT). The Kaplan-Meier survival curves for the three groups are shown in Figure 1 . All-cause mortality was not significantly different between groups (Figure 2) .
In spite of this, the overall relation between BP and the event rate was stronger with respect to ABP than to OBP Hazard ratio (HR) 1.26, Po0.01 vs 1.17, Po0.05 pr. 10 mmHg increment in systolic BP).
The WCE was not found to be related to event rate neither in the whole population nor in any of the three groups alone. Furthermore, we have earlier shown that the dipping status did not differ between 10-year follow-up of WCH PH Gustavsen et al the three groups 13 and the daytime-night-time BP difference did not affect the results of the study.
When included in a Cox-regression model, statistically significant predictors of cardiovascular events were the BP group, WCH HR 6.6 (Po0.001), EH hazard ratio (Po0.001) compared to NT, systolic daytime ABP, age and sex (Po0.01), smoking history and diabetes (Po0.05), whereas previous cardiovascular events, BMI, systolic OBP, diastolic daytime ABP and WCE were not. The findings were identical when applying the composite end point of major cardiovascular events instead of the primary composite end point in the calculations.
When the calculations were performed using the lower cutoff of 135/85 mmHg, only 40 (9.5%) of the referred hypertensives were WCH. Nevertheless, when included in a Cox-regression model with daytime ABP, age, sex, smoking history and diabetes, WCH was still associated with a significantly increased cardiovascular event rate compared to NT (Po0.01).
Discussion
The main finding of this study is a significantly increased risk of cardiovascular events in WCH compared to normal controls. The risk amounts to the same level as seen in the EH patients in spite of the fact that the WCHs at inclusion had an ABP level that was actually lower than in the NT group.
The Kaplan-Meier curves (Figure 1) show that the course of the WCH and EH patients are practically superimposed, but they diverge from the control group almost instantaneously and the difference steadily increases throughout the 10 years of observation. It should be realized that at some period during follow-up, 85% of the EH group and 60.3% of the WCH group were treated with antihypertensive medication, so the increased risk Duration of follow-up (days) Figure 2 Kaplan-Meier survival curves of total mortality in the WCH, the EH and the NT groups (P ¼ NS, overall and between groups).
10-year follow-up of WCH
PH Gustavsen et al in the WCH's should be seen in this context. The control group in this study is older than the hypertensive groups and when we adjust for age in a Cox-regression analysis, the dispersion becomes even more pronounced. After adjustment for other potential confounders (gender, smoking history, ABP, OBP, BMI, antihypertensive treatment, previous cardiovascular event), WCH is still a potent predictor of cardiovascular morbidity and mortality. This finding of an increased risk in the WCH patients is surprising and in contrast with the previously mentioned prognostic studies on WCH. [5] [6] [7] [8] In the study by Verdecchia et al, 5 there were similar survival curves for WCHs and the control group, whereas the EHs separated almost immediately to a higher event rate. However, there have been some discussions of these results because a low ABP cutoff level was used in this study and because a substantial fraction of the patients had been treated with antihypertensive drugs. Furthermore, the study gives no answer to the development beyond 3.2 years. Fagard et al 7 studied data from the placebo-treated arm of the SYST-EUR trial, where 20% of the patients had WCH. After 4.4 years of follow-up, there was a clearly lower event rate in the WCH group compared to the EH group. The study by Khattar et al 6 is the only previous study with long-term follow-up, namely 9.1 years. The patients were referred hypertensives examined primarily with intra-arterial ABPM; the frequency of WCH was 15% and these patients also had a significantly lower event rate than EH. However, the studies by Fagard and Khattar did not include a normal control group, so comparison between WCHs and NTs was not possible. Finally, Kario et al 8 recently showed that WCHs and controls had fewer cerebrovascular events than did EHs over a 3.5-year period.
Our results are even more interesting since we have earlier found in cross-sectional data on the same individuals that cardiac and renal involvement in WCH was lower than in EH patients and in the same level as in NT. [10] [11] [12] 16 In spite of our specific results on the WCH group, this study reveals quite expected overall relations between cardiovascular events and BP data. We found that the event rate was more strongly predicted from ABP than OBP. And importantly, we have earlier found ABP to be a better predictor of target-organ damage than OBP on cross-sectional data in this study population. 10, 11 Longitudinal results have been published by others both in normotensive and in hypertensive populations and they show the same relations as our prospective results. [17] [18] [19] The high event rate in the WCH group raises the important question of whether there is also a positive relation between WCE and cardiovascular morbidity rate in our population. This was not the case, neither if the referring doctor's OBP, nor if our own OBP were used to calculate the WCE. These results are also in accordance with our previously published cross-sectional data.
We expected, based on our own earlier studies 13, 16 and the prospective studies already mentioned above, WCH to be an innocent condition. How can we then explain that WCHs seems to carry an increased risk compared to NTs? WCH patients had as per definition much lower ABP F in the level of the NT groupFat the time of enrolment in the study. Our data show, as mentioned earlier, that ABP had a clearly stronger association to morbidity than did OBP. And we could not show any overall relation between WCE and morbidity. Thus, factors other than the BP that we have measured at baseline must be accounting for this increased risk in the specific WCH group. Some of the factors that could explain the excess morbidity are summarized below.
* WCH has been suggested to be a condition with a general hyper-reactivity of the BP, therefore an increased and potentially harmful BP variability could be present, although the average ABP values were normal. Our previous studies 13, 16 have not made us believe that the WCHs, in general, have an increased variability. Also, we find only very limited data to support the fact that variability as measured by indirect ABPM is connected with increased target organ damage.
20,21
* Regression towards the mean of the ABP measurements results in misclassification of some patients since the definition of WCH makes use of a cutoff level. This means that some patients analysed as WCHs are actually hypertensives and hence tend to aggravate the findings in the WCH group. However, this error only gives rise to a minor change in the total BP load of the individuals and it can only explain a minor fraction of the difference. * It has been proposed that WCH is a prehypertensive state and accordingly the individuals who develop established hypertension (EH) will carry this increased risk. However, to date there are only very limited data on the development of ABP in these patients. We await further studies on this aspect, but development of EH may turn out to explain some of the findings that we have obtained in this study and may also be the explanation why our results differ from the four studies published so far, since the followup period in three 5, 7, 8 of these was below 4.4 years. * Finally, a potentially important explanation regarding why our results are diverging from other prognostic studies may lie in the way our patients were selected. 16 Our hypertensive patients are almost entirely recruited from GPs, whom they may have sought because of a specific health problem. They may therefore differ considerably from patients who are controlled for a stable condition (eg hypertension), who again may differ from individuals invited to participate in a study. 22 This means that quite different types of patients may be classified as WCH in different studies and hence very different results may evolve. We hypothesize that an important reason for an increased risk in a fraction of these patients is due to the fact that they seek their doctor for a particular problem; the patient may fear to be ill, he/she may actually be ill or he/she may be aware of exposition to risk factors; these are all conditions that may be associated with excess morbidity and mortality. 16 Whatever is the cause of the visit a pressor response may be evoked, and because a BP measurement is so frequently made at a clinic visit, there will be a tendency to change the focus to an occasionally raised BP and accordingly WCH will be associated with an increased risk. In other words, some of the WCHs are not healthy; that is why they visit their doctor, but the problem is not the BP.
It is a limitation of our study that we have no baseline biochemical tests including lipid analyses, blood glucose, etc on our study population, and we therefore cannot weigh the impact of these risk factors. However, a number of previous studies have not shown any difference between WCH and NT individuals with respect to these measures. [23] [24] [25] Other important risk factors like tobacco smoking, heredity for hypertension and male gender were not over-represented in the WCH group compared to the NT group. Another limitation could be the relatively high diastolic cutoff level of 90 mmHg in daytime ABP. However, this was protocollated when we designed our initial cross-sectional study and we found that the prevalence of target-organ damage below this BP value is comparable to the control level. Nonetheless, the ABPs in WCHs were lower than those in the NT, so this cannot explain the increased risk in the WCH group. Finally, we have recalculated the data with a lower cutoff o135/ 85 mmHg, but although the number of WCH patients is reduced, they still had a significantly higher cardiovascular event rate than the NT group.
In conclusion, we have, based per protocol on a daytime ABP partition value of o135/90 mmHg, divided our hypertensive patients into WCHs (n ¼ 76) and EHs (n ¼ 344). After 10 years of follow-up, our data reveal that this approach does not identify a WCH group with a low risk of cardiovascular complications as compared to patients with EH. The risk was the same in the two hypertensive groups and significantly higher than in the normal control group, even though the WCH patient had the lowest ABP of the three groups. Furthermore, when we define WCH on a daytime ABP 135/85 mmHg, we find exactly the same excess risk.
Based on these results, we strongly recommend that WCH patients are followed carefully with regular checks of BP and complete cardiovascular risk profile.
